tbuckley/cabot-search huggingface dataset:
HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
Authors: Sophie Le Grand, Juliette Villemonteix, Etienne Daguindau, Marylise Fort, Sophie Caillat‐Zucman, Vincent Allain, Anne Dormoy, Veronique De Mas, Eric Delabesse, Christian Recher, Regis Peffault de Latour, Nicolas Vallet, David Michonneau, Sarah Guenounou, Anne Huynh
Journal: HemaSphere (2025)

Abstract Donor lymphocyte infusion (DLI) prevents acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) relapses following hematopoietic stem cell transplantation. Given the life‐threatening toxicities such as graft versus host disease (GVHD), the identification of variables associated with response without toxicities is warranted. We hypothesized that HLA evolutionary divergence (HED), defined by the diversity between two given alleles of the same HLA gene, may be such a factor. A retrospective multicenter case‐control study was conducted to evaluate the outcomes of pre‐emptive (preDLI) and prophylactic DLI (proDLI) regarding their HED score, in AML or MDS patients. DLI‐treated patients were matched with controls (1:2 matched) from French transplantation centers according to hospital, hemopathy, donor type, and risk classification. In total, 201 patients were included ( N = 147 in the preDLI group, N = 54 in the proDLI group). Relapse‐free survival was significantly better in the preDLI group (hazard ratio [HR] = 0.23, 95% confidence interval [CI]: 0.14–0.55, p &lt; 0.001) than in controls. However, this benefit was offset by a higher incidence of severe GVHD (HR = 4.88, 95% CI: 2.30–10.32, p &lt; 0.001). HED A, B, C, DQA1, DQB1, DPB1, and DRB1 were calculated for 65 DLI‐treated patients. High‐class II HED was significantly associated with higher GVHD and relapse‐free survival (GRFS, HR = 0.33, 95% CI: 0.20–0.77, p = 0.005). Specific DQAB associations directly improved GRFS (HR = 0.23, 95% CI: 0.09–0.58, p = 0.004). In conclusion, screening the class II HED score identifies patients eligible for DLI treatment who will benefit the most from this strategy.
Hierarchical Interconnected Porous Scaffolds with Regulated Interfacial Nanotopography Exhibit Antimicrobial, Alleviate Inflammation, Neovascularization, and Tissue Integration for Bone Regeneration
Authors: Shirun Chu, Linlong Li, Jiahao Zhang, Jing You, Xiaolan Li, Yuanyuan Zhou, Xiao Huang, Qiaoli Wu, Fang Chen, Xue Bai, Huan Tan, Jie Weng
Journal: Biomaterials (2025)
Preventing HIV in women in Africa
Authors: Frances M. Cowan, Maryam Shahmanesh, Paul A. Revill, Joanna Busza, Euphemia L. Sibanda, Sungai T. Chabata, Natsayi Chimbindi, Tamara Choola, Owen Mugurungi, James R. Hargreaves, Andrew N. Phillips
Journal: Nature Medicine (2025)
Angiotensin 1-7 and a TERT activator individually restore vasodilatory capacity within the microcirculation previous SARS-CoV-2 infection
Authors: Yoshinori Nishijima, Shelby N Hader, Erin C Birch, Yiliang Chen, Michael E Widlansky, Andreas M Beyer
Journal: Cardiovascular Research (2025)

Journal Article Accepted manuscript Angiotensin 1-7 and a TERT activator individually restore vasodilatory capacity within the microcirculation previous SARS-CoV-2 infection Get access Yoshinori Nishijima, Yoshinori Nishijima Department of Medicine, Medical College of Wisconsin, Milwaukee, WisconsinCardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin https://orcid.org/0000-0002-5547-4508 Search for other works by this author on: Oxford Academic PubMed Google Scholar Shelby N Hader, Shelby N Hader Department of Medicine, Medical College of Wisconsin, Milwaukee, WisconsinCardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin https://orcid.org/0000-0002-6564-091X Search for other works by this author on: Oxford Academic PubMed Google Scholar Erin C Birch, Erin C Birch Department of Medicine, Medical College of Wisconsin, Milwaukee, WisconsinCardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin Search for other works by this author on: Oxford Academic PubMed Google Scholar Yiliang Chen, Yiliang Chen Department of Medicine, Medical College of Wisconsin, Milwaukee, WisconsinVersiti Blood Research Institute, Milwaukee, Wisconsin Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael E Widlansky, Michael E Widlansky Department of Medicine, Medical College of Wisconsin, Milwaukee, WisconsinCardiovascular Center, Medical College of Wisconsin, Milwaukee, WisconsinDepartment of Pharmacology, Medical College of Wisconsin, Milwaukee, Wisconsin Search for other works by this author on: Oxford Academic PubMed Google Scholar Andreas M Beyer Andreas M Beyer Department of Medicine, Medical College of Wisconsin, Milwaukee, WisconsinCardiovascular Center, Medical College of Wisconsin, Milwaukee, WisconsinDepartment of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin Correspondence: Andreas. M. Beyer, 8701 Watertown Plank Rd., Medical College of Wisconsin, Milwaukee, WI 53226 (E-mail: [email protected]) https://orcid.org/0000-0001-9129-7492 Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, cvaf020, https://doi.org/10.1093/cvr/cvaf020 Published: 13 February 2025 Article history Received: 19 September 2024 Revision received: 10 December 2024 Accepted: 20 December 2024 Published: 13 February 2025
Anti-myxovirus resistance protein 1: a novel biomarker for autoimmune myositis and interstitial lung disease in systemic lupus erythematosus
Authors: Eugene Krustev, Marvin J Fritzler, Sasha Bernatsky, Yvan St Pierre, Paul J Sciore, Evelyne Vinet, Christian A Pineau, Arielle Mendel, Fares Kalache, Louis-Pierre Grenier, Thaisa Cotton, Omid Zahedi Niaki, May Y Choi
Journal: Annals of the Rheumatic Diseases (2025)
Injectable hydrogel microspheres promoting inflammation modulation and nucleus pulposus-like differentiation for intervertebral disc regeneration
Authors: Yuhang Chen, Zhuo-Ran Yang, Zhangrong Cheng, Pengzhi Shi, Anran Zhang, Jing-Wen Fan, Zhiguo Zhao, Hao Jiang, Jintao Zhu, Yukun Zhang
Journal: Journal of Controlled Release (2025)
Loss of ATG7 in microglia impairs UPR, triggers ferroptosis, and weakens amyloid pathology control
Authors: Zhangying Cai, Shoutang Wang, Siyan Cao, Yun Chen, Silvia Penati, Vincent Peng, Carla M. Yuede, Wandy L. Beatty, Kent Lin, Yiyang Zhu, Yingyue Zhou, Marco Colonna
Journal: The Journal of Experimental Medicine (2025)

Microglia impact brain development, homeostasis, and pathology. One important microglial function in Alzheimer's disease (AD) is to contain proteotoxic amyloid-β (Aβ) plaques. Recent studies reported the involvement of autophagy-related (ATG) proteins in this process. Here, we found that microglia-specific deletion of Atg7 in an AD mouse model impaired microglia coverage of Aβ plaques, increasing plaque diffusion and neurotoxicity. Single-cell RNA sequencing, biochemical, and immunofluorescence analyses revealed that Atg7 deficiency reduces unfolded protein response (UPR) while increasing oxidative stress. Cellular assays demonstrated that these changes lead to lipoperoxidation and ferroptosis of microglia. In aged mice without Aβ buildup, UPR reduction and increased oxidative damage induced by Atg7 deletion did not impact microglia numbers. We conclude that reduced UPR and increased oxidative stress in Atg7-deficient microglia lead to ferroptosis when exposed to proteotoxic stress from Aβ plaques. However, these microglia can still manage misfolded protein accumulation and oxidative stress as they age.
Evolution of Critical Care Cardiology: An Update on Structure, Care Delivery, Training, and Research Paradigms: A Scientific Statement From the American Heart Association
Authors: Shashank S. Sinha, Bram J. Geller, Jason N. Katz, Cynthia Arslanian-Engoren, Christopher F. Barnett, Erin A. Bohula, Abdulla A. Damluji, Venu Menon, Robert O. Roswell, Saraschandra Vallabhajosyula, Amanda R. Vest, Sean van Diepen, David A. Morrow
Journal: Circulation (2025)

Critical care cardiology refers to the practice focus of and subspecialty training for the comprehensive management of life-threatening cardiovascular diseases and comorbid conditions that require advanced critical care in an intensive care unit. The development of coronary care units is often credited for a dramatic decline in mortality rates after acute myocardial infarction throughout the 1960s. As the underlying patient population became progressively sicker, changes in organizational structure, staffing, care delivery, and training paradigms lagged. The coronary care unit gradually evolved from a focus on rapid resuscitation from ventricular arrhythmias in acute myocardial infarction into a comprehensive cardiac intensive care unit designed to care for the sickest patients with cardiovascular disease. Over the past decade, the cardiac intensive care unit has continued to transform with an aging population, increased clinical acuity, burgeoning cardiac and noncardiac comorbidities, technologic advances in cardiovascular interventions, and increased use of temporary mechanical circulatory support devices. Herein, we provide an update and contemporary expert perspective on the organizational structure, staffing, and care delivery in the cardiac intensive care unit; examine the challenges and opportunities present in the education and training of the next generation of physicians for critical care cardiology; and explore quality improvement initiatives and scientific investigation, including multicenter registry initiatives and randomized clinical trials, that may change clinical practice, care delivery, and the research landscape in this rapidly evolving discipline.
Optimized suction patch design for enhanced transbuccal macromolecular drug delivery
Authors: David Klein Cerrejon, Hanna Krupke, Daniel Gao, Nevena Paunović, David Sachs, Jean-Christophe Leroux
Journal: Journal of Controlled Release (2025)

Peptides represent a rapidly expanding class of drugs with broad therapeutic potential. However, due to their large molecular weight and susceptibility to degradation in the gastrointestinal tract, most peptide drugs are administered via subcutaneous (SC) injections. Despite extensive research, a painless broad delivery platform for these drugs is still lacking. Recently, an octopus-inspired buccal patch has shown promise in addressing this challenge by leveraging a synergistic combination of mechanical stretching and permeation enhancers. In this study, the patch and the loaded formulation were optimized to improve ease of use, scalability, and efficacy. Through assessments of mechanical properties, finite element simulations, and ex vivo experiments, we evaluated the effects of patch design and material, as well as the drug matrix composition and the formulation preparation methods on the delivery performance. A patch with a > 9-fold larger effective surface area, produced via mold casting of medical-grade silicone (shore hardness 50) and loaded with a lyophilized drug matrix, emerged as the most promising system. In beagle dogs, 30-min application of this patch resulted in a 14.6 % bioavailability for teriparatide (4118 g mol-1), while bioavailability of semaglutide (4114 g mol-1) was 9.6 times higher than the commercial tablet. This works showcases how systematic optimization of this technology can improve and simplify the buccal administration of macromolecular drugs, facilitating the clinical translation of this non-invasive dosage form.
Prediabetes remission to reduce the global burden of type 2 diabetes
Authors: Leontine Sandforth, Stephanie Kullmann, Arvid Sandforth, Andreas Fritsche, Reiner Jumpertz-von Schwartzenberg, Norbert Stefan, Andreas L Birkenfeld
Journal: Trends in Endocrinology and Metabolism (2025)

Prediabetes is a highly prevalent and increasingly common condition affecting a significant proportion of the global population. The heterogeneous nature of prediabetes presents a challenge in identifying individuals who particularly benefit from lifestyle or other therapeutic interventions aiming at preventing type 2 diabetes (T2D) and associated comorbidities. The phenotypic characteristics of individuals at risk for diabetes are associated with both specific risk profiles for progression and a differential potential to facilitate prediabetes remission and reduce the risk of future T2D. This review examines the current definition and global prevalence of prediabetes and evaluates the potential of prediabetes remission to reduce the alarming increase in the global burden of T2D.
Questioning the sixth mass extinction
Authors: John J Wiens, Kristen E Saban
Journal: Trends in Ecology & Evolution (2025)

The idea that Earth is currently experiencing a sixth mass extinction is widespread. We critically evaluate this claim. Very few studies have tested this idea. Some studies showed that recent extinction rates are faster than fossil background rates, but extinction rates can exceed background rates outside mass extinctions. Other studies extrapolated from recent extinctions to project 75% global species loss. But these recent extinctions were mostly of island species. No cause was specified for these future extinctions, and >50% of assessed species are considered non-threatened. We find numerous other issues. Proponents of the sixth mass extinction have made invaluable contributions by highlighting recent extinctions, but these extinctions may not be equivalent to past mass extinctions or relevant to current threats.
Correction: CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes
Authors: Jie Li, Xinya Gao, Zhanqiang Zhang, Yuanhui Lai, Xunxun Lin, Bo Lin, Maoguang Ma, Xiaoli Liang, Xixi Li, Weiming Lv, Ying Lin, Nu Zhang
Journal: Molecular Cancer (2025)
Integrated biomimetic bioprinting of perichondrium with cartilage for auricle reconstruction
Authors: Litao Jia, Siyu Liu, Luosha Gu, Xiaomin Liu, Kexin Sun, Feiyang Chu, Jinshi Zeng, Wenshuai Liu, Haiyue Jiang, Xia Liu
Journal: Bioactive Materials (2025)
A role for Arginase in skin epithelial differentiation and anti-microbial peptide production
Authors: Denis C Szondi, Rachel A Crompton, Linus Oon, Nagavidya Subramaniam, Khek-Chian Tham, Lee Sze Han, Helen Williams, Joanne Pennock, Thiam C Lim, Carine Bonnard, Jason Wong, Leah A Vardy, Sheena M Cruickshank
Journal: British Journal of Dermatology (2025)

Abstract Background and objectives Arginase1 (ARG1) is an enzyme expressed by keratinocytes that drives several functions linked to skin barrier function. However, the mechanisms underpinning keratinocyte ARG1 function in barrier homeostasis is not fully elucidated. Atopic dermatitis (AD) is linked to impaired skin barrier via altered keratinocyte differentiation and susceptibility to infection. Therefore, we investigated the role of ARG1 in keratinocyte differentiation and anti-microbial responses. Methods In vitro 2D differentiation assays using ARG knockdown or ARG inhibited keratinocytes were used to explore the function of ARG1 in keratinocyte differentiation and barrier formation. ARG1 was also assessed in an ex vivo model of AD. Results ARG1 was strongly expressed in the apical layers of human skin, corresponding with high ARG1 expression in late differentiated keratinocytes. ARG was downregulated in an ex vivo AD model relative to controls, suggesting altered ARG1 is clinically relevant. ARG1 inhibition in keratinocytes led to a significant decrease in late differentiation markers Filaggrin (FLG), Involucrin (IVL), and Loricrin (LOR) and significant downregulation of the Anti-microbial Peptides (AMPs), Lipocalin 2 (LCN2), Kallikreins (KLKs) and Small Proline Rich Proteins (SPRRs). ARG forms part of the urea cycle and the action of ARG on L- arginine causes the production of L-ornithine and urea. L-ornithine, in turn, is catabolised for putrescine (Put) production. Supplementation with ARG products, Put and urea, could rescue late keratinocyte differentiation and AMP expression in ARG deficient cells. Conclusions ARG1 activity plays a major role in keratinocyte differentiation and AMP production. ARG1 is downregulated in AD, but in cell systems is amenable to rescue by ARG1 downstream products Put and urea. Manipulation of the ARG1 pathway may, therefore, have potential to be used for the management of skin conditions such as AD.
Genetic and anatomical determinants of olfaction in dogs and wild canids
Authors: Alice Mouton, Deborah Bird, Gang Li, Brent A Craven, Jonathan M Levine, Marco Morselli, Matteo Pellegrini, Blaire Van Valkenburgh, Robert K Wayne, William J Murphy
Journal: Molecular Biology and Evolution (2025)

Abstract Understanding the anatomical and genetic basis of complex phenotypic traits has long been a challenge for biological research. Domestic dogs offer a compelling model as they demonstrate more phenotypic variation than any other vertebrate species. Dogs have been intensely selected for specific traits and abilities, directly or indirectly, over the past 15,000 years since their initial domestication from the gray wolf. Because olfaction plays a central role in critical tasks, such as the detection of drugs, diseases, and explosives, as well as human rescue, we compared relative olfactory capacity across dog breeds and assessed changes to the canine olfactory system to their direct ancestors, wolves and coyotes. We conducted a cross-disciplinary survey of olfactory anatomy, olfactory receptor (OR) gene variation, and OR gene expression in domestic dogs. Through comparisons to their closest wild canid relatives, the gray wolf and coyote, we show that domestic dogs might have lost functional OR genes commensurate with a documented reduction in nasal morphology as an outcome of the domestication process prior to breed formation. Critically, within domestic dogs alone, we found no genetic or morphological profile shared among functional or genealogical breed groupings, such as scent hounds, that might indicate evidence of any human-directed selection for enhanced olfaction. Instead, our results suggest that superior scent detection dogs likely owe their success to advantageous behavioral traits and training rather than an “olfactory edge” provided by morphology or genes.
Association Between Self-Monitored Blood Glucose and Continuous Glucose Monitoring in Youth With Type 1 Diabetes and Medicaid Insurance
Authors: Janice Chan, Nicholas Jackson, Arianna Gonzalez Rebollar, Cynthia Santana, Giselle Perez de la Garza, Tannaz Moin, Jennifer K. Yee, Estelle Everett
Journal: Diabetes Care (2025)

OBJECTIVE Youth with type 1 diabetes (T1D) and Medicaid must demonstrate they have self-monitored their blood glucose level at least four times daily to receive continuous glucose monitors (CGMs). New California Medicaid policies eliminated this requirement and, thus, CGM access has increased. This study examines whether infrequent baseline self-monitored blood glucose (SMBG) checks result in suboptimal outcomes or nonadherence with CGM use. RESEARCH DESIGN AND METHODS This retrospective study included youth with T1D and Medicaid who started CGM after January 2019, when newer models no longer needed calibration, at two large health care systems. Patients were stratified by data on baseline SMBG frequency (&amp;lt;4 vs ≥4 checks daily) collected at the clinic visit prior to starting CGM. Differences between SMBG groups in CGM adherence and HbA1c over time were assessed by a mixed-effects linear regression model and fixed-effect interaction term. Patients were surveyed to explore individual impact of CGM on diabetes management. RESULTS We followed 78 youth for 6 months. CGM adherence was similar between SMBG frequency groups at 3 months (68.7 vs. 68.4%; P = 0.97) and sustained at 6 months. HbA1c values improved in both groups at 3 months, with a larger improvement in those with SMBG &amp;lt;4 daily checks (1.3% vs. 0.4%), and sustained at 6 months. Patient surveys (n = 35) reported high engagement with CGM and increased insulin boluses after initiation. CONCLUSIONS Patients using CGM demonstrated improvement in HbA1c regardless of prior SMBG. Increased engagement with CGM likely promoted increased insulin boluses. Therefore, restriction of CGM to those with SMBG ≥4 daily checks is an unnecessary barrier, excluding those who could potentially benefit the most.
Structural basis for channel gating and blockade in tri-heteromeric GluN1-2B-2D NMDA receptor
Authors: Hyunook Kang, Max Epstein, Tue G Banke, Riley Perszyk, Noriko Simorowski, Srinu Paladugu, Dennis C Liotta, Stephen F Traynelis, Hiro Furukawa
Journal: Neuron (2025)
The Glycemic Impact of Protein Ingestion in People With Type 1 Diabetes
Authors: Giang M. Dao, Greg M. Kowalski, Clinton R. Bruce, David N. O’Neal, Carmel E. Smart, Dessi P. Zaharieva, Declan T. Hennessy, Sam Zhao, Dale J. Morrison
Journal: Diabetes Care (2025)

In individuals with type 1 diabetes, carbohydrate is commonly recognized as the primary macronutrient influencing postprandial glucose levels. Accumulating evidence indicates that protein ingestion also contributes to the increment in postprandial glucose levels, despite endocrine and metabolic responses different from those with carbohydrate ingestion. However, findings regarding protein ingestion’s glycemic effect in people with type 1 diabetes are equivocal, with the magnitude of glycemic response seemingly dependent on the rate of absorption and composition of protein ingested. Therefore, the aim of this article is to outline the physiological mechanisms by which ingested protein influences blood glucose regulation in individuals with type 1 diabetes and provide clinical implications on use of dietary protein in the context of glycemic management. Specifically, protein ingestion raises plasma amino acid levels, which directly or indirectly (via gut hormones) stimulates glucagon secretion. Together with the increase in gluconeogenic precursors and an absent endogenous insulin response in individuals with type 1 diabetes, this provides a synergistic physiological environment for increased endogenous glucose production and subsequently increasing circulating glucose levels for several hours. While there is a dearth of well-controlled studies in this area, we provide clinical implications and directions for future research regarding the potential for using ingestion of fast-absorbing protein (such as whey protein) as a tool to prevent and mitigate overnight- and exercise-induced hypoglycemia in people with type 1 diabetes.